Fran Hawthorne

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

Adult patients with binge eating disorder who were treated for 12 weeks with lisdexamfetamine dimesylate reported having 4 fewer binge days per week, and also experienced improvements in weight and triglyceride levels.

Patients in a trial of a first-in-class medication for the treatment of female sexual dysfunction reported improvement in overall sexual function, including an increase in the number of satisfying sexual events, and a concomitant decrease in distress levels associated with sexual dysfunction.

Study results presented at the 2014 annual meeting of the American Psychiatric Association show that a reduced dosage of the antidepressant vilazodone is as effective as the currently approved dosage.

Study results presented at the 2014 APA annual meeting show patients treated with vortioxetine significant improvement in composite cognition scores compared to patients treated with placebo, independent of the drug's effect on their depression symptoms.

Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.

By paralyzing the facial muscles involved in producing frown lines, onabotulinumtoxinA injection seems to alleviate depression, especially among patients who exhibit a high degree of hyperactivity.

Small, "naturalistic" study shows treatment with desvenlafaxine produces high rates of symptom improvement and remission with low rates of adverse events in patients with major depressive disorder.

The opioid overdose epidemic and resulting focus on preventing opioid abuse and diversion could threaten access to effective medications for patients with legitimate medical needs.